# Pneumonia

Dr. Ibrahim Al-Homood

• Community-acquired pneumonia (CAP) is defined as an acute pneumonia occurring in persons who have not been hospitalized recently and are not living in facilities such as nursing homes

## Risk factors

- COPD
- cardiovascular disease
- diabetes mellitus
- Smoking
- Alcoholism
- neurologic diseases that increase the risk of aspiration

# Causative organism



- Haemophilus influenzae and Moraxella catarrhalis are also common pathogens.
- *Klebsiella pneumoniae* is reported in patients with alcoholism.
- Pseudomonas aeruginosa in patients with chronic underlying structural lung disease

- Staphylococcus aureus
- 1. when CAP occurs following influenza
- 2. in patients with cavitary pneumonia in whom there are no risk factors for aspiration
- 3. in injection drug users
- 4. in patients with a recent history of skin and soft tissue infection.

## C/F

#### BOX 43-1

#### SYMPTOMS OF COMMUNITY-ACQUIRED PNEUMONIA

Fever or hypothermia

Rigors, sweats

New cough with or without sputum production

Hemoptysis

Change in character of respiratory secretions in a patient with chronic cough

Chest discomfort

Dyspnea

Anorexia, fatigue, or myalgias

# Diagnosis

- The acute onset of cough (especially with purulent sputum production), fever, chills, pleuritic chest pain, and dyspnea is characteristic of pneumonia.
- The presentation may be much more nonspecific in elderly patients.
- Tachypnea is the most sensitive finding suggesting pneumonia in elderly.

- CBC
- U&E
- CXR
- SPUTUM C/S
- BLOOD C/S
- Legionella antigen









### Treatment

- Admission OR NO ???
- 1 CURB-65
- 2 PSI
- ③ IDSA/ATS

# Poor prognostic factors

- 1 Old age
- (2) Multi-lobar
- (3) Bacteremia
- 4 Sever associated disease
- (5) Immunosuppression

Table 14. IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia
Clinical Criteria
Confusion (new-onset disorientation to person, place, or time)
Hypothermia (core temperature <36.0 °C [96.8 °F])
Respiration rate ≥30/min <sup>a</sup>
Hypotension necessitating aggressive fluid resuscitation
Multilobar pulmonary infiltrates
Laboratory Criteria
Arterial Po₂/Fio₂ ratio ≤250ª
Leukopenia (<4000 cells/µL [4.0 × 10 <sup>9</sup> /L])
Thrombocytopenia (<100,000 /μL [10 × 10 <sup>9</sup> /L])
Blood urea nitrogen >20 mg/dL (7.1 mmol/L)
μL = microliter; IDSA/ATS = Infectious Diseases Society of America/American Thoracic Society.

#### • outpatient antibiotics for 5-7 days

Table 15. Antibiotic The	erapy for Community-Acquired	Pneumonia in Outpatients
--------------------------	------------------------------	--------------------------

Risk Factors	Treatment
Previously healthy and no risk factor(s) for drug-resistant Streptococcus pneumoniae	Macrolide (azithromycin, clarithromycin, or erythromycin) or doxycycline
Risk factor(s) for drug-resistant <i>S. pneumoniae</i> or underlying comorbidities	Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) or β-lactam <sup>a</sup> plus a macrolide or doxycycline

<sup>&</sup>lt;sup>a</sup>Amoxicillin, 1 g every 8 hours, or amoxicillin-clavulanate, 2 g every 12 hours (preferred), or cefpodoxime or cefuroxime, 500 mg twice daily (alternative).

#### Table 16. Empiric Antibiotic Therapy for Community-Acquired Pneumonia in Inpatients

Inpatient Setting	Treatment
Medical ward	β-lactam <sup>a</sup> plus a macrolide or doxycycline; or respiratory fluoroquinolone (moxifloxacin, gemifloxacin or levofloxacin)
Intensive care unit	β-lactam <sup>b</sup> plus either azithromycin or a fluoroquinolone <sup>c</sup> ; if penicillinallergic, a respiratory fluoroquinolone <sup>d</sup> plus aztreonam
If risk factor(s) for Pseudomonas aeruginosa or gram-negative rods on sputum Gram stain	Antipseudomonal β-lactam with pneumococcal coverage (cefepime, imipenem, meropenem, or piperacillin-tazobactam) plus ciprofloxacin or levofloxacin (750 mg); or antipseudomonal β-lactam with pneumococcal coverage plus an aminoglycoside plus azithromycin; or antipseudomonal <sup>e</sup> β-lactam with pneumococcal coverage plus an aminoglycoside plus a respiratory fluoroquinolone
If risk factor(s) for CA-MRSA or compatible sputum Gram stain	Add vancomycin or linezolid to β-lactam <sup>b</sup> plus either azithromycin or a fluoroquinolone <sup>c</sup>

CA-MRSA = community-associated methicillin-resistant Staphylococcus aureus.

<sup>a</sup>Cefotaxime, ceftriaxone, or ampicillin; ertapenem is an alternative in patients with an increased risk of enteric gram-negative pathogens (not *P. aeruginosa*).

<sup>b</sup>Cefotaxime, ceftriaxone, or ampicillin-sulbactam.

<sup>c</sup>Moxifloxacin, gemifloxacin, ciprofloxacin, or levofloxacin.

<sup>d</sup>Moxifloxacin, gemifloxacin, or levofloxacin.

 $^{\mathrm{e}}$ Aztreonam can be used in a patient with a severe  $\beta$ -lactam allergy.

## When to shift to PO?

#### • Clinical stability are met

- 1 temperature  $\leq 37.8 \,^{\circ}\text{C} \, [100.0 \,^{\circ}\text{F}]$
- (2) PR  $\leq 100$ /min
- (3) RR  $\leq 24$ /min
- (4) SBP ≥90 mm Hg
- $\bigcirc$  arterial oxygen saturation  $\geq$ 90% or PO<sub>2</sub>  $\geq$  60 mm Hg [7.9 kPa]
- 6 ability to tolerate oral intake
- (7) normal mental status

### Hospital-Acquired Pneumonia Ventilator-Associated Pneumonia

- HAP is defined as a pneumonia that occurs 48 hours or more after hospital admission that was not incubating at the time of admission.
- VAP is defined as pneumonia that develops more than 48 hours after beginning mechanical ventilation.

## Risk factors

- Old age
- Altered mental status
- Underlying chronic lung disease
- Neurologic disease
- Previous antibiotic use
- Abdominal or thoracic surgery
- Mechanical ventilation
- Recent large-volume aspiration
- Nasogastric intubation

## Treatment goals

- (1) treat early
- (2) administer empiric broad-spectrum antimicrobial agents
- (3) de-escalate antimicrobial coverage when appropriate
- (4) consider short-duration therapy (7-8 days) whenever feasible.